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Abstract
Background The manipulations, casts, and Botox
method for treating idiopathic clubfoot is an alternative
non-surgical treatment method. Botox-induced reversible
muscle paralysis of the gastrocsoleus enables a physician to
manipulate and cast the clubfoot in greater dorsiflexion.
Ultrasound is incorporated during the early treatment
stages to monitor the underlying physiology of the muscle–
tendon unit following Botox.
Methods Ultrasonographic evaluation was performed
parallel to a double-blind randomized control trial admin-
istering Botox or placebo to correct clubfoot. Patients
underwent two-dimensional ultrasound to monitor the
length changes to the gastrocsoleus and Achilles tendon
unit at two time points: pre-injection (baseline) and
6 weeks post-blinded injection. Gastrocsoleus and Achilles
tendon length measurements were analyzed among
placebo, Botox and contralateral controls using repeated
measures ANOVA.
Results The baseline gastrocsoleus length of the clubfoot
(322.4 pixels) before blinded injection appears shorter than
controls (337.5 pixels), but fails to reach significance
(p = 0.05). The complex length within each of the three
treatment groups displayed no significant change between
baseline and 6 weeks. The complex–tendon ratio and
muscle–tendon ratio of the Botox treatment group was
significantly decreased compared to controls (p = 0.049
and 0.042, respectively). Briefly, when expressed as a
proportion, an increase in Achilles tendon length and
decrease in gastrocsoleus is observed when clubfeet are
treated with Botox.
Conclusions Only in the Botox treatment cohort did the
muscle shrink to uncover tendon (seen as a decreased
complex–tendon ratio and muscle–tendon ratio) over the
6-week interval to effectively increase tendon length with
respect to the unit as a whole.
Keywords Clubfoot  Ultrasound  Achilles tendon 
Gastrocsoleus  Botox  Onabotulinumtoxin A
Introduction
Various techniques for the treatment of clubfoot have
been utilized, with a current focus on non-surgical tech-
niques and their associated advantages [1]. The Ponseti
method has emerged as one of the most commonly used
methods. Its initial treatment phase utilizes serial manip-
ulations and casts and typically requires an Achilles
tenotomy for correction of the equinus deformity [2].
Ultrasound analysis with a minimum 1-year follow-up
post-tenotomy reveal an Achilles tendon with unorganized
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fibre structure and isolated thickening in the sectioned
region [3, 4].
In 2000, an alternative approach to correcting clubfoot
was developed, which implements serial manipulations and
casts with the adjuvant therapy of onabotulinumtoxin A
(Botox), referred to as the MCB method [5, 6]. Botox
allows for the correction of hindfoot equinus, without
disrupting the integral muscle–tendon unit.
Injection of Botox into skeletal muscle initiates a
signal cascade, which leads to temporary muscle paralysis
of the targeted muscle complex. Before Botox is endo-
cytosed at the pre-synaptic nerve terminal it is cleaved into
a light chain and a heavy chain. The heavy chain allows for
selective uptake into the pre-synaptic nerve terminal at the
neuromuscular junction. Within the nerve terminal the light
chain’s protease activity is activated by the acidic envi-
ronment, which then permits the light chain to cleave
SNARE proteins, inhibiting the release of synaptic vesicles
containing the neurotransmitter, acetylcholine [7]. New
nerve sprouts extend into the affected area and produce
synaptic activity by approximately 50 days. At 3 months
post-injection the new nerve sprouts regress and activity of
the original nerve terminals is rejuvenated [8].
The physiological and biomechanical changes induced
by Botox on the skeletal muscle complex [9–12] and the
accompanying tendon [13–15] have been studied in animal
models. Previous research has utilized ultrasound to cap-
ture the changes to human muscle architecture post-botu-
linum toxin-A injection in adult stroke patients [16].
However, to the best of our knowledge there is no literature
investigating the effect that Botox elicits on the structure
of the human postnatal muscle–tendon unit using
ultrasound.
To investigate the effect of Botox therapy on the
gastrocsoleus and Achilles tendon unit of idiopathic club-
foot, we conducted a two-dimensional (2-D) ultrasound
study parallel to a double-blind randomized control trial,
thereby providing the opportunity to monitor the response




A total of 36 clubfoot participants were enrolled in the
double-blind randomized control trial at BC Children’s
Hospital (BCCH) between March 2006 and January 2011.
Twenty-eight patients were included in the ultrasound
study (Fig. 1). Contralateral feet of subjects diagnosed with
a unilateral clubfoot were examined by the orthopaedic
surgeon (C.A.) and served as controls.
Treatment protocol
Upon presentation to BCCH Clubfoot Clinic, clubfoot
subjects are treated according to the manipulation and cast,
injection, and bracing techniques thoroughly described in
previous work [6]. Dimeglio [17] and Pirani [18] scores for
each clubfoot are measured at the initial visit. The moment
during the manipulation and casting phase at which the
forefoot can be abducted beyond 60 but hindfoot equinus
persists is referred to as hindfoot stall. Further intervention
is required to attain full correction and is therefore fol-
lowed by a blinded injection of either botulinum toxin
type-A (Botox; Allergan, Inc.) or placebo (unpreserved
saline). Randomization was by patient and determined by a
computer-generated randomization table. An unblinded
pharmacist prepared the Botox and placebo syringes. One
orthopaedic surgeon (C.A.) administered every blinded
injection. The quantity of Botox or placebo administered
is determined according to the patient’s weight, at a dose of
10 U/kg or 0.1 ml/kg, respectively. The site of injection, as
described previously, is the gastrocsoleus muscle belly [6].
For subjects with bilateral clubfeet, the total injection dose
is divided equally between the two limbs. All clubfeet were
then casted post-blinded injection until full correction was
achieved. Correction was then maintained by full-time use
of the Dennis Browne bar and corrective shoes. At 6 weeks
post-blinded injection a handheld goniometer was used to
measure dorsiflexion in flexion (DFF) and dorsiflexion in
extension (DFE) for the affected foot.
The ultrasound study focused on two time points:
baseline and 6 weeks post-blinded treatment. Baseline was
defined as the moment at which the clubfoot reaches
hindfoot stall.
Data collection
The ultrasound evaluation was performed in the radiology
department using an Acuson Sequoia 512 ultrasound unit
(Siemens Medical) with a high-resolution linear 15L8W
probe. Static images and perspective extended field of view
images using Siescape technology were obtained.
The infant was placed prone with knee straight and the
foot protruding off the edge of the bed so that it could be
readily grasped and dorsiflexed, attempting to achieve 90
between the tibia and foot plantar surface and create a
uniform measuring situation. The fixed point for Achilles
tendon insertion was the posterior superior corner of the
calcaneous bone. The chosen surrogate for origin of gas-
trocsoleus muscle was the superior lateral margin of the
tibia. In Siescape mode, a probe runs smoothly between
these two points to produce an extended field of view
image. Three suitable images per limb were obtained.
Two paediatric radiologists performed the study, one of
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whom (D.J.) did all the post-imaging calculations. The
extended field of view images are composite images pro-
viding pixel distances, not direct millimeter measurement.
Thus a ratio of ‘‘lateral superior tibia’’ to ‘‘posterior
superior calcaneous’’ (representing the muscle tendon
complex) divided by the ‘‘posterior superior calcaneous’’ to
‘‘Achilles aponeurosis’’ (representing the upper limit of the
Achilles tendon) was calculated (Fig. 2). To account for
the potential error associated with the difficultly in pre-
cisely delineating the aponeurosis, both measurements
were obtained three times per limb. An average value for
each measure was calculated for analysis.
Statistical analysis
Measurements collected at baseline were evaluated
between two groups: clubfoot and control. Complex,
muscle, tendon, complex–tendon (CT) ratio, and muscle–
tendon (MT) ratio measurements for the two groups were
compared using a one-tailed t-test with equal variance
assumed.
Complex, muscle, tendon, CT ratio, and MT ratio
measurements for Botox, placebo, and control groups at
baseline and 6 weeks post-blinded injection were com-
pared using repeated measures ANOVA (IBM SPSS Sta-
tistics, Version 21).
Results
The distribution of demographics, initial severity scores,
and range of motion for clubfoot subjects in the study are
presented in Table 1. No adverse drug events occurred
during the course of the study.
Baseline data comparing pre-injected clubfeet to con-
trols (Table 2) characterize a clubfoot with an increased
Original Clubfoot Cohort in RCT Trial 
36 Subjects (72 feet)
Lost to follow-up
1 Subject (2 feet)
Incomplete Ultrasound
6 Subjects (12 feet)
Clubfoot Cohort for Ultrasound Study










1 Subject (2 feet)
Fig. 1 Overview of subjects in
randomized control trial (RCT)
ultrasound study
Fig. 2 Ultrasound image
depicting measurements of
(a) Achilles tendon length and
(b) gastrocsoleus muscle and
Achilles tendon complex length
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Achilles tendon length, decreased complex length, and
decreased gastrocsoleus muscle length. These differences
did not, however, reach statistical significance.
The average lengths and ratios obtained from the gas-
trocsoleus and Achilles tendon unit for each treatment
group at both time intervals are summarized in Table 3.
Repeated measures ANOVA found no significant dif-
ference within each of the three treatment groups with
respect to baseline and 6-week time measurements for the
complex, tendon, and muscle lengths (Online Resource 1).
Analysis of baseline and 6 weeks post-length measure-
ments between the three treatment groups was assessed
among five parameters: complex (F2,52 = 2.500,
p = 0.092); tendon (F2,52 = 1.732, p = 0.187); muscle
(F2,52 = 4.919, p = 0.011); CT ratio (F2,52 = 3.131,
p = 0.052); and MT ratio (F2,52 = 3.294, p = 0.045).
Accompanying pairwise comparisons between Botox or
placebo groups and control are summarized in Table 4. Of
heightened importance is the MT ratio (p = 0.042) and CT
ratio (p = 0.049) of the Botox group exhibiting a sig-
nificant change over time compared to controls, whilst the
placebo ratios displayed no difference from controls (MT
ratio p = 0.265, CT ratio p = 0.288).
The pairwise comparisons revealed no significant dif-
ference between the placebo and Botox groups with
respect to tendon (p = 0.759), muscle (p = 1.000), and
complex (p = 1.000) length. Similarly, the CT ratio
(p = 1.000) and MT ratio (p = 1.000) showed no signifi-
cant difference between placebo and Botox treatment.
Repeated measures ANOVA found no significant inter-
action, indicating that the three treatment groups behaved
similarly over the two time points (Online Resource 2).
To summarize the results: (1) no significant lengthening
of the gastrocsoleus–tendon complex for the three groups
was observed over a 6-week interval, (2) a certain amount
of tendon creep is seen with casting alone, and (3) only the
Botox group showed increased tendon length and
decreased muscle length when expressed as a proportion.
Discussion
Incorporation of 2-D ultrasound in the double-blind random-
ized control trial investigating Botox versus placebo for
clubfoot correction enabled our team to monitor the under-
lying physiological response to the treatment. The main
results describe the clubfoot cohort’s Achilles tendon and
gastrocsoleus lengths before blinded intervention, and iden-
tify the underlying changes to the muscle–tendon unit at
6 weeks post-blinded treatment. Ultrasound evaluation of the
Achilles tendon after exposure to Botox depicts a significant
decrease in MT ratio and CT ratio over the 6-week time frame.
After a thorough review, we found limited literature that
used ultrasound to describe the gastrocsoleus and Achilles
tendon complex lengths of an untreated clubfoot [19]. Our
findings show that the post-natal clubfoot appears to have a
shorter gastrocsoleus muscle length; this value, however,
falls short of reaching significance. Ultrasound measure-
ments of the gastrocsoleus and Achilles tendon of subjects
Table 1 Study participant demographics and measurements
Total subjects 28
Gender
Female 6 (21 %)
Male 22 (79 %)
Average age (months)
Baseline 1.44 ± 0.44
6 weeks post-treatment 2.83 ± 0.40














a Measurements collected at first visit to BC Children’s Hospital
clubfoot clinic
b Dimeglio scores based on 31 clubfeet
Table 2 Mean baseline ultrasound length measurements of clubfoot and control muscle–tendon complexes
Complex Tendon Muscle Muscle–tendon ratio Complex–tendon ratio
Clubfoot (n = 40) 454.6 132.2 322.4 2.49 3.50
Control (n = 15) 464.6 127.1 337.5 2.72 3.72
P valuea 0.14 0.18 0.05 0.07 0.07
All measurements recorded in pixel units
a One-tailed t test between clubfoot and controls at baseline
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with cerebral palsy (CP) present findings similar to our
clubfoot study. Children with spastic CP have a shorter
gastrocsoleus muscle belly length than normally developed
children [20–22]. A decrease in fascicle length is noted not to
be the underlying cause for this discrepancy [21, 23]. Fur-
thermore, children with spastic CP and equinus gait have
longer Achilles tendons than controls [22]. While our base-
line analysis of the clubfoot muscle–tendon unit character-
izes a longer Achilles tendon, this value does not reach
significance. It is postulated for the CP population that in
order to accommodate for the shortened gastrocsoleus, the
increased Achilles tendon length enables the muscle–tendon
unit to extend through a suitable range of motion [24].
Tendons are the principal elastic component of the
muscle–tendon complex, harnessing the ability to trans-
form energy and transmit force [25–27]. Ultrasound studies
examining the Achilles tendon of children with clubfoot
pre- and post-tenotomy reveal a successful continuous
tendon approximately 3–6 weeks post-operatively [3, 4,
28, 29]. However, long-term ultrasound studies show per-
sistent scar thickening of the cut tendon and irregularities
of the tendon fibres [3, 4]. These ultrasound findings are
presumably related to gait analysis results post-tenotomy,
describing clubfoot subjects with a decrease in ankle power
generation of 17 % [30].
The goal of an Achilles tenotomy in the setting of
clubfoot is to lengthen the tendon and thereby the muscle–
tendon unit, which allows for increased dorsiflexion of the
ankle. A typically developed tendon is predominantly
comprised of collagen type I [31]. During the healing
phases of a ruptured Achilles tendon, tenocytes fill the
gap with a significantly increased amount of collagen type
III fibres [32]. Collagen type III fibres are thinner and as a
result have a decreased ability to withstand tensile forces
[33]. This divergence from the natural microanatomy of a
tendon likely reduces the viscoelastic properties of the
muscle tendon unit and alters the effective lever arm,
resulting in decreased power generation. Botox pre-
sumably does not modify the elastic modulus or the
architecture of the integral Achilles tendon. Additionally,
a tenotomy causes measurable recoil in the associated
muscle complex, leading to shortening of that particular
muscle [34].
Tendons have a number of thoroughly established vi-
soelastic properties, one of which is the model termed
tendon creep. This visoelastic property states that when a
tendon is held under constant tension a noticeable increase
in tendon length is observed. This phenomenon can be seen
when an individual is treated with corrective braces or
casts, and highlights the ability of a tendon to respond to an
external stress by increasing its strain, allowing for bio-
mechanical equilibrium to be re-established [25, 35].
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lengthening of the Achilles tendon observed in our placebo
and Botox treatment groups, both of which received
manipulations and casts. Importantly, once the desired
range of motion is achieved, the creep needs to be con-
tinually preserved through a maintenance program.
The model of Achilles tendon creep perhaps initially
seems counterintuitive with respect to the mechanism of
Botox. However, Botox causes reversible muscle
paralysis of the gastrocsoleus, which removes the antago-
nistic contraction of the shortened muscle against the
Achilles tendon. This enables the clubfoot to be manipu-
lated and held through an extended range of dorsiflexion,
which is sustained by casts, and the resultant tensile force
is applied unobstructedly on the Achilles tendon. There-
fore, the applied stretch is increased and consequently
facilitates creep of the Achilles tendon.
A decrease in both the MT ratio and CT ratio following
Botox intervention indicates an underlying change in the
composition of the muscle–tendon unit. The placebo group
behaves in a similar manner with respect to Achilles tendon
and gastrocsoleus lengths over time, but the ratios are not
significantly different from controls. The larger decrease in
muscle length for the Botox group is potentially
explained by the knowledge that the slack sarcomere
length, muscle mass, and fibre cross-sectional area of
muscle (normal rat model) treated with Botox is
decreased compared to untreated controls [12]. The short-
ened gastrocsoleus length seen in neutral position, how-
ever, does not seem to influence the clinical range of
motion of the clubfoot (DFF = 27.6, DFE = 22.1).
Alternatively, if a muscle injected with Botox is analyzed
for maximal length, an increase in length is observed [36].
Future studies of this nature should include ultrasound
imaging of the foot in varying degrees of flexion and
extension. This would permit added insight into the effect
of Botox on the complex and allow for investigation of
muscle and tendon length relationships with range of
motion parameters.
There are a few limitations to this study that warrant
consideration when interpreting the results. Foot pressure
analysis characterizes the unaffected contralateral foot as
having significantly different plantar pressure profiles
compared to the feet of normally developed individuals
[37, 38]. These findings do not indicate a direct irregularity
in the underlying anatomy of the contralateral clubfoot, but
should be taken into consideration, as our control group
consisted solely of contralateral feet.
Further consideration should also be made when
extending the findings of this study to postulate the effects
Botox will have on a typically developed muscle and
tendon, as histological investigation into the pathology of
the affected clubfoot muscle has produced conflicting
results [39–41].
To gain further insight into the physiological effect of
Botox on the injected gastrocsoleus and Achilles tendon
unit, future clinical research should implement a validated
3-D ultrasound technique [42, 43].
Injection of Botox into the gastrocsoleus of a club-
foot with persistent hindfoot equinus enables redistribu-
tion of the muscle–tendon unit. Botox-induced muscle
paralysis allowed for increased Achilles tendon length at
the expense of muscle. Consideration should be directed
towards the benefits of a long duration of non-tensile
muscle and the effective pain management that Botox
provides.
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Table 4 Pairwise comparisons
between placebo, Botox, and
control
All measurements recorded in
pixel units
a Negative value indicates the
placebo or Botox
measurement is less than control
*Statistically significant
Pairwise comparison Mean differencea Standard error p Value
Complex Control Placebo -17.009 8.053 0.118
Botox -13.933 7.713 0.230
Tendon Control Placebo 3.432 5.007 1.000
Botox 8.693 4.796 0.227
Muscle Control Placebo -20.442 8.005 0.041*
Botox -22.627 7.667 0.014*
Muscle–tendon ratio Control Placebo -0.226 0.130 0.265
Botox -0.316 0.124 0.042*
Complex–tendon ratio Control Placebo -0.224 0.132 0.288
Botox -0.314 0.127 0.049*
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